Cytori Therapeutics (CYTX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Remains Bullish on Cytori Therapeutics (CYTX) Following Q4 Results; Affirms at 'Buy'
March 4, 2016 12:36 PM ESTRoth Capital reaffirmed its Buy rating and $1.50 price target on Cytori Therapeutics (Nasdaq: CYTX) following Q4 results and update issued Thursday night. Cytori reported a relatively inline Q4 loss of $0.03 per share.
Analyst Joseph Pantginis offered the... More
